Table 4 Diagnostic Characteristics of Functional Testing, Semi-Quantitative Coronary Artery Calcification Assessment, and Primary Prevention Guidelines in the Entire Cohort
Full Cohort (n = 159) | MACE | No MACE | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | PLR (95% CI) | NLR (95% CI) |
|---|---|---|---|---|---|---|---|---|
Functional Study |  |  | 26.3% (13.4%—43.1%) | 94.2% (88.4%—97.6%) | 58.8% (36.9%—77.8%) | 80.3% (77.0%—83.2%) | 4.55 (1.86 – 11.13) | 0.78 (0.64 – 0.95) |
 Abnormal | 10 | 7 | ||||||
 Normal | 28 | 114 | ||||||
Coronary Artery Calcifications (CAC) |  |  | 63.2% (46.0%—78.2%) | 71.1% (62.1%—79.0%) | 40.7% (32.1%—49.8%) | 86.0% (80.0%—90.4%) | 2.18 (1.51 – 3.16) | 0.52 (0.34 – 0.80) |
 Present | 24 | 35 | ||||||
 Absent | 14 | 86 | ||||||
Moderate or Severe CAC |  |  | 29.0% (15.4%—45.9%) | 95.0% (89.5%—98.2%) | 64.7% (42.1%—82.2%) | 81.0% (77.6%—84.0%) | 5.84 (2.31 – 14.73) | 0.75 (0.61 – 0.92) |
 Present | 11 | 6 | ||||||
 Absent | 27 | 115 | ||||||
2019 ACC/AHA Guidelinea |  |  | 26.3% (13.4%—43.1%) | 88.5% (81.1%—93.7%) | 43.5% (26.9%—61.7%) | 78.1% (74.5%—81.4%) | 2.29 (1.09 – 4.78) | 0.83 (0.68 – 1.02) |
 Recommend statin therapy discussion | 10 | 13 | ||||||
 Do not recommend statin therapy discussion | 28 | 100 |